The Co-Chaperone Hch1 Regulates Hsp90 Function Differently than Its Homologue Aha1 and Confers Sensitivity to Yeast to the Hsp90 Inhibitor NVP-AUY922

被引:24
|
作者
Armstrong, Heather [1 ]
Wolmarans, Annemarie [1 ]
Mercier, Rebecca [1 ]
Mai, BaoChan [1 ]
LaPointe, Paul [1 ]
机构
[1] Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB, Canada
来源
PLOS ONE | 2012年 / 7卷 / 11期
基金
加拿大健康研究院;
关键词
SACCHAROMYCES-CEREVISIAE HSP90; MOLECULAR CHAPERONE; COCHAPERONE AHA1; MIDDLE DOMAIN; ATP BINDING; IN-VIVO; ANTITUMOR-ACTIVITY; ESSENTIAL PROTEIN; EXPRESSION; COMPLEX;
D O I
10.1371/journal.pone.0049322
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hsp90 is a dimeric ATPase responsible for the activation or maturation of a specific set of substrate proteins termed 'clients'. This molecular chaperone acts in the context of a structurally dynamic and highly regulated cycle involving ATP, co-chaperone proteins and clients. Co-chaperone proteins regulate conformational transitions that may be impaired in mutant forms of Hsp90. We report here that the in vivo impairment of commonly studied Hsp90 variants harbouring the G313S or A587T mutation are exacerbated by the co-chaperone Hch1p. Deletion of HCH1, but not AHA1, mitigates the temperature sensitive phenotype and high sensitivity to Hsp90 inhibitor drugs observed in Saccharomyces cerevisiae that express either of these two Hsp90 variants. Moreover, the deletion of HCH1 results in high resistance to Hsp90 inhibitors in yeast that express wildtype Hsp90. Conversely, the overexpression of Hch1p greatly increases sensitivity to Hsp90 inhibition in yeast expressing wildtype Hsp90. We conclude that despite the similarity between these two co-chaperones, Hch1p and Aha1p regulate Hsp90 function in distinct ways and likely independent of their roles as ATPase stimulators. We further conclude that Hch1p plays a critical role in regulating Hsp90 inhibitor drug sensitivity in yeast.
引用
收藏
页数:13
相关论文
共 38 条
  • [21] Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery
    Meyer, P
    Prodromou, C
    Liao, CY
    Hu, B
    Roe, SM
    Vaughan, CK
    Vlasic, I
    Panaretou, B
    Piper, PW
    Pearl, LH
    EMBO JOURNAL, 2004, 23 (03) : 511 - 519
  • [22] Aha1 regulates Hsp90's conformation and function in a stoichiometry-dependent way
    Mondol, Tanumoy
    Silbermann, Laura-Marie
    Schimpf, Julia
    Vollmar, Leonie
    Hermann, Bianca
    Tych, Katarzyna
    Hugel, Thorsten
    BIOPHYSICAL JOURNAL, 2023, 122 (17) : 3458 - 3468
  • [23] Hsp90 and its co-chaperone, Sgt1, as autoantigens in dilated cardiomyopathy
    Kapustian, Lyudmila L.
    Vigontina, Olga A.
    Rozhko, Olga T.
    Ryabenko, Dmytro V.
    Michowski, Wojciech
    Lesniak, Wieslawa
    Filipek, Anna
    Kroupskaya, Irina V.
    Sidorik, Lyudmila L.
    HEART AND VESSELS, 2013, 28 (01) : 114 - 119
  • [24] 2-phenylethynesulphonamide (PFT-) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels
    Yeramian, Andree
    Vea, Alvar
    Benitez, Sandra
    Ribera, Joan
    Domingo, Monica
    Santacana, Maria
    Martinez, Montserrat
    Maiques, Oscar
    Valls, Joan
    Dolcet, Xavier
    Vilella, Ramon
    Cabiscol, Elisa
    Matias-Guiu, Xavier
    Marti, Rosa M.
    PIGMENT CELL & MELANOMA RESEARCH, 2016, 29 (03) : 352 - 371
  • [25] The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop
    Schmid, Andreas B.
    Lagleder, Stephan
    Graewert, Melissa Ann
    Roehl, Alina
    Hagn, Franz
    Wandinger, Sebastian K.
    Cox, Marc B.
    Demmer, Oliver
    Richter, Klaus
    Groll, Michael
    Kessler, Horst
    Buchner, Johannes
    EMBO JOURNAL, 2012, 31 (06) : 1506 - 1517
  • [26] Hsp90 Cochaperone Aha1 Is a Negative Regulator of the Saccharomyces MAL Activator and Acts Early in the Chaperone Activation Pathway
    Ran, Fulai
    Gadura, Nidhi
    Michels, Corinne A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (18) : 13850 - 13862
  • [27] 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft
    Munnink, Thijs H. Oude
    de Korte, Maarten A.
    Nagengast, Wouter B.
    Timmer-Bosscha, Hetty
    Schroder, Carolina P.
    de Jong, Johan R.
    van Dongen, Guus A. M. S.
    Jensen, Michael Rugaard
    Quadt, Cornelia
    Lub-de Hooge, Marjolijn N.
    de Vries, Elisabeth G. E.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (03) : 678 - 684
  • [28] The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
    Park, Kang-Seo
    Oh, Bora
    Lee, Mi-Hee
    Nam, Ky-Youb
    Jin, Hae Ran
    Yang, Hannah
    Choi, Junyoung
    Kim, Sang -We
    Lee, Dae Ho
    CANCER LETTERS, 2016, 372 (01) : 75 - 81
  • [29] Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone
    Singh, Jay K.
    Hutt, Darren M.
    Tait, Bradley
    Guy, Naihsuan C.
    Sivils, Jeffrey C.
    Ortiz, Nina R.
    Payan, Ashley N.
    Komaragiri, Shravan Kumar
    Owens, Jazzmin Jovonna
    Culbertson, David
    Blair, Laura J.
    Dickey, Chad
    Kuo, Szu Yu
    Finley, Dan
    Dyson, H. Jane
    Cox, Marc B.
    Chaudhary, Jaideep
    Gestwicki, Jason E.
    Balch, William E.
    CELL CHEMICAL BIOLOGY, 2020, 27 (03): : 292 - +
  • [30] HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
    Lee, Dae-Hee
    Sung, Ki Sa
    Bartlett, David L.
    Kwon, Yong Tae
    Lee, Yong J.
    CELLULAR SIGNALLING, 2015, 27 (02) : 293 - 305